Cigna (CI)
Health Care · Managed Health Care · NYSE
A diversified global health services organization providing integrated pharmacy benefits and comprehensive health insurance solutions.
What Cigna does
The Cigna Group is a global health company that provides insurance and health services. Its operations include pharmacy benefit management, specialty pharmacy services, and a wide array of health insurance products, including medical, dental, behavioral health, and supplemental benefits.
Themes: pharmacy benefit management (PBM), managed care, health services, specialty pharmacy
Fundamentals
- Price$277.51 as of 2026-08-21 close
- Market cap$73.3B as of 2026-08-21
- 1-year return-7.8% 2025-08-21 close $300.95 → 2026-08-21 close $277.51
- P/E11.52 as of 2026-08-24
- Net margin+2.3% as of 2026-08-24
- Gross margin+9.1% as of 2026-08-24
- ROE+15.2% as of 2026-08-24
- Debt / equity0.75 as of 2026-08-24
- Revenue growth (YoY)+7.8% as of 2026-08-24
- Revenue CAGR (3y)+15.0% SEC XBRL
- Beta0.29 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.7%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How CI compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CI is not currently in any published Top 10 list. Its scores are below.
Long-term score
51.6 #432 of 987 scored · #25 of 57 in Health Care
Valuation 84th (price to earnings 11.5, price to book 1.7) and capital return 71st (consecutive years of dividend increases 5 years); weakest is financial health (29th, free cash flow margin 3.2%, debt to equity 0.7).
Short-term score
40.7 #1360 of 1,704 scored · #210 of 240 in Health Care
Volume and participation 54th: trading volume is about normal versus its 30-day average; catalysts 43rd: the analyst consensus rating is unchanged since the prior reading; weakest is momentum 29th: MACD momentum is negative.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, CI's dividend was covered by reported results (earnings payout 7%, operating-cash-flow payout 4%). This describes past coverage, not a forecast.
- Earnings payout7% dividends / net income
- Operating-cash-flow payout4% dividends / operating cash flow — capital spending was not reported, so this does not subtract it
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Cigna looks technically
Cigna (CI) is trading 0.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 47 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 13 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 0.2% below its 200-day average, the long-term trend line — a long-term downtrend | -0.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $284.60 | $284.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $278.13 | $278.13 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 285.7. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 47 trading days ago — a "golden cross", a bullish long-term signal | 47 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend) | 11.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($263.11 to $285.70) — its "stochastic" reading is 64 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 63.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $315.47 | $315.47 |
|---|---|---|
| From the 52-week high | it is 12.0% below its 52-week high (its highest price of the past year) | -12.0% |
| Above the 52-week low | it is 15.9% above its 52-week low (its lowest price of the past year) | +15.9% |
| Below the 52-week high | it is 12.0% below its highest point of the past year | 12.0% |
| Since a 20-day breakout | it made a new 20-day low about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day low about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $370.82 (set on 2024-09-16) | $370.82 |
| Given back of the 52-week move | over the past year its closes ranged ($244.41 to $311.00), and it has recovered around half of its fall from last year’s high — 50% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $285.56 to $287.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 28 days, so it is a narrow thing to be measuring a retracement against. | 49.7% |
| From the all-time high | it is 25.2% below its all-time high | -25.2% |
| Nearest price level | it is trading 1.0% below a resistance level at $280.25 — a price it turned at six times since 2025-09-25, most recently on 2026-07-16. Since 2024-08-21 it has 3 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $8.00 (set on 2008-11-21) | $8.00 |
| Above the all-time low | it is 3368.9% above its all-time low | +3,369% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.47 between its high and its low — about 2.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.47 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $265.35 and $295.96 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $265.35 – $280.65 – $295.96 |
| Typical daily range (% of price) | its price moves about 2.7% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.7% |
| Stretch from the 200-day average | it is trading 0.1 daily ranges below its 200-day average price (0.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.23× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 3.5% below the previous close 16 sessions ago and has not traded back through the level it left behind at 296.47 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.5% |
| Gap filled | a 2.1% gap down opened on 2026-08-05 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.8 percentage points (the stock lost 4.5% while the market gained 2.3%) | -6.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.7 percentage points (the stock lost 1.6% while the market gained 3.1%) | -4.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 12.1 percentage points (the stock lost 1.0% while the market gained 11.1%) | -12.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 28.3 percentage points (the stock lost 7.8% while the market gained 20.5%) | -28.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.8% of the share price, which is taken to mean a barrier that gives way easily. | -3.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $279.96 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -0.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $277.29 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +0.1% |
Price levels it has turned at before
CI last closed at $277.51 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $280.25 | Resistance | 1.0% above the last close | turned there six times · 2025-09-25 to 2026-07-16 |
| $273.04 | Support | 1.6% below the last close | turned there 7 times · 2025-11-12 to 2026-07-01 |
| $266.22 | Support | 4.1% below the last close | turned there 8 times · 2024-12-17 to 2026-08-05 |
| $289.84 | Resistance | 4.4% above the last close | turned there six times · 2025-10-16 to 2026-08-10 |
| $297.07 | Resistance | 7.0% above the last close | turned there five times · 2025-05-15 to 2026-06-12 |
| $257.79 | Support | 7.1% below the last close | turned there four times · 2025-08-01 to 2026-03-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $285.70.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $218.42 and $244.12 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $285.70.
This reading has stood for 5 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · trendless / choppy (low ADX) · lagging the market · Trading at this year’s average price paid (anchored VWAP) · Trading below the Ichimoku cloud · Near a resistance level (pressing into a price that has capped it before) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 24 analysts
- Mean price target$341.42 range $290.00 – $400.00; median $343.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CI
- Consensus EPS estimate$7.50 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Exposure to evolving and complex government regulations in health care and pharmacy benefits.","Risk of adverse changes in medical costs or pharmacy benefit obligations.","Significant dependence on pharmacy and health service contracts and government programs."]
What changed in the latest 10-Q
AI-assisted comparison of CI's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'March 31, 2026' as the financial condition comparison date in the opening paragraph (newer filing, filed 2026-04-30)
- Added reference to 'three months ended March 31, 2026' for results of operations comparison (newer filing, filed 2026-04-30)
- Added reference to '2025 Form 10-K' for the year ended December 31, 2025 (newer filing, filed 2026-04-30)
- Added paragraph referencing 'Note 15 to the Consolidated Financial Statements' for reconciliation details and segment revenue discussion (newer filing, filed 2026-04-30)
- Added risk factor language: 'our ability to manage health care costs and respond to price competition, inflation and other pressures' (newer filing, filed 2026-04-30)
- Added risk factor language: 'our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care' (newer filing, filed 2026-04-30)
- Removed:
- Removed reference to 'September 30, 2025' as the financial condition comparison date (older filing, filed 2025-10-30)
- Removed reference to 'December 31, 2024' as comparison date (older filing, filed 2025-10-30)
- Removed reference to 'three and nine months ended September 30, 2025' for results of operations comparison (older filing, filed 2025-10-30)
- Removed reference to '2024 Form 10-K' (older filing, filed 2025-10-30)
- Removed reference to 'Part I, Item 1A of our 2024 Form 10-K' for Risk Factors (older filing, filed 2025-10-30)
- Removed risk factor language: 'our ability to achieve our strategic and operational initiatives' (older filing, filed 2025-10-30)
- Removed risk factor language: 'our ability to adapt to changes in an evolving and rapidly changing industry' (older filing, filed 2025-10-30)
- Removed risk factor language: 'our ability to compete effectively, differentiate our products and services from those of our competitors, and maintain or increase market share' (older filing, filed 2025-10-30)
- Removed risk factor language: 'our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks' (older filing, filed 2025-10-30)
- Reworded:
- Changed 'Special items are matters that management believes are not representative of the underlying results of operations' to 'Special items are matters that management believes are not representative of the underlying results of normal, recurring operations' in adjusted income definition (newer filing, filed 2026-04-30)
- Changed 'Special items are matters that management believes are not representative of the underlying results of operations' to 'Special items are matters that management believes are not representative of the underlying results of normal, recurring operations' in adjusted revenues definition (newer filing, filed 2026-04-30)
- Notes:
- The newer filing text appears truncated at the end of the forward-looking statements section, making a complete comparison of risk factors impossible
- The older filing text is also truncated at the end, preventing full assessment of all changes in the risk factors section
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($268452) — 1 selling insider
- Last 180 days0 buys · 14 sells ($59M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 24 matched disclosures for CI from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding CI as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 46,972,115
- Reported value $12,529,811,874
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 5 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CI had 4,766,977 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CI had 1.80% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.55 days to cover at the same settlement.
- Reported short interest (shares) 4,766,977
- Short interest (% of shares outstanding) 1.80%
- Prior settlement (shares) 6,178,422
- Reported change -22.84%
- Days to cover (reported) 2.55
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CI vs…
Cigna is found in…
Frequently asked questions
What does Cigna (CI) do?
The Cigna Group is a global health company that provides insurance and health services. Its operations include pharmacy benefit management, specialty pharmacy services, and a wide array of health insurance products, including medical, dental, behavioral health, and supplemental benefits.
What sector is Cigna (CI) in?
Cigna (CI) is classified in the Health Care sector. Its industry is Managed Health Care. It trades on NYSE.
Does CI pay a dividend?
Yes — Cigna (CI) pays a dividend, with an indicated yield of about 1.74% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Cigna's (CI) competitors?
Notable peers of Cigna (CI) include UnitedHealth Group, CVS Health, Elevance Health, Humana and Centene. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in CI?
Yes — we hold 24 matched STOCK Act disclosures for CI from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Cigna (CI) overbought or oversold right now?
Cigna (CI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CI come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.